Aankondiging • May 30
Gedeon Richter PLC Approves Dividend for the Financial Year 2025 The Annual General Meeting of Gedeon Richter Plc. held on 29 April 2026 approved to pay a dividend of HUF 120,000 million in respect of the 2025 financial year. The details of the dividend payment process were published by the Company on 26 May 2026. Gedeon Richter Plc. directly and indirectly owns 3,295,804,C" series Richter common shares. The dividend on treasury shares will be distributed to those shareholders eligible for such dividend, in proportion to their number of shares. Based on the Company's current number of treasury shares, Gedeon Richter Plc. pays HUF 655.4545 dividend per share. Board Change • May 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Group Head of Controlling, CFO & Director Laszlo Kovacs was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • Apr 08
Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026 Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026. Aankondiging • Nov 28
SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER). SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025.
The transaction has received approval from Antimonopoly Committee of Ukraine. Aankondiging • Jul 02
Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and Osteoporosis Gedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy. Aankondiging • May 14
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025. Aankondiging • Apr 09
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025 Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025. Aankondiging • Dec 10
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025 Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025. Reported Earnings • Nov 14
Third quarter 2024 earnings released: EPS: Ft203 (vs Ft294 in 3Q 2023) Third quarter 2024 results: EPS: Ft203 (down from Ft294 in 3Q 2023). Revenue: Ft216.7b (up 15% from 3Q 2023). Net income: Ft37.1b (down 32% from 3Q 2023). Profit margin: 17% (down from 29% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year. Reported Earnings • Aug 07
Second quarter 2024 earnings released: EPS: Ft383 (vs Ft155 in 2Q 2023) Second quarter 2024 results: EPS: Ft383 (up from Ft155 in 2Q 2023). Revenue: Ft216.3b (up 6.1% from 2Q 2023). Net income: Ft70.0b (up 144% from 2Q 2023). Profit margin: 32% (up from 14% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • May 29
Upcoming dividend of Ft423 per share Eligible shareholders must have bought the stock before 05 June 2024. Payment date: 13 June 2024. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 4.6%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (2.3%). Board Change • May 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Peter Cserhati was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 15
First quarter 2024 earnings released: EPS: Ft373 (vs Ft210 in 1Q 2023) First quarter 2024 results: EPS: Ft373 (up from Ft210 in 1Q 2023). Revenue: Ft203.4b (down 3.0% from 1Q 2023). Net income: Ft68.2b (up 74% from 1Q 2023). Profit margin: 34% (up from 19% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Declared Dividend • Apr 29
Dividend of Ft423 announced Shareholders will receive a dividend of Ft423. Ex-date: 5th June 2024 Payment date: 13th June 2024 Dividend yield will be 1,855%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (266% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 59% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • Apr 11
High number of new directors Independent Director Peter Cserhati was the last director to join the board, commencing their role in 2023. Reported Earnings • Apr 07
Full year 2023 earnings released: EPS: Ft860 (vs Ft907 in FY 2022) Full year 2023 results: EPS: Ft860 (down from Ft907 in FY 2022). Revenue: Ft805.2b (flat on FY 2022). Net income: Ft158.9b (down 6.0% from FY 2022). Profit margin: 20% (down from 21% in FY 2022). Products in clinical trials Phase I: 4 Phase II: 1 Phase III: 1 Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 03
Full year 2023 earnings released: EPS: Ft860 (vs Ft835 in FY 2022) Full year 2023 results: EPS: Ft860 (up from Ft835 in FY 2022). Revenue: Ft805.2b (flat on FY 2022). Net income: Ft158.9b (up 2.1% from FY 2022). Profit margin: 20% (in line with FY 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 10
Third quarter 2023 earnings released: EPS: Ft294 (vs Ft442 in 3Q 2022) Third quarter 2023 results: EPS: Ft294 (down from Ft442 in 3Q 2022). Revenue: Ft188.5b (down 13% from 3Q 2022). Net income: Ft54.6b (down 34% from 3Q 2022). Profit margin: 29% (down from 38% in 3Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year. Aankondiging • Nov 04
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. Aankondiging • Nov 03
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO® Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. Aankondiging • Sep 17
Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of Endometriosis Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen. New Risk • Aug 07
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (127% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Reported Earnings • Aug 06
Second quarter 2023 earnings released: EPS: Ft155 (vs Ft411 in 2Q 2022) Second quarter 2023 results: EPS: Ft155 (down from Ft411 in 2Q 2022). Revenue: Ft203.8b (up 5.6% from 2Q 2022). Net income: Ft28.7b (down 62% from 2Q 2022). Profit margin: 14% (down from 40% in 2Q 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 31
Upcoming dividend of Ft390 per share at 4.5% yield Eligible shareholders must have bought the stock before 07 June 2023. Payment date: 15 June 2023. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.5%). Reported Earnings • May 14
First quarter 2023 earnings released: EPS: Ft210 (vs Ft199 in 1Q 2022) First quarter 2023 results: EPS: Ft210 (up from Ft199 in 1Q 2022). Revenue: Ft209.7b (up 25% from 1Q 2022). Net income: Ft39.2b (up 5.8% from 1Q 2022). Profit margin: 19% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 06
Full year 2022 earnings released Full year 2022 results: Revenue: Ft802.8b (up 27% from FY 2021). Net income: Ft155.6b (up 11% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). Products in clinical trials Phase III: 1 Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Aankondiging • Feb 09
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 12 non-independent directors. Member of Executive Board & Director Istvan Hamecz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 06
Second quarter 2022 earnings released: EPS: Ft411 (vs Ft151 in 2Q 2021) Second quarter 2022 results: EPS: Ft411 (up from Ft151 in 2Q 2021). Revenue: Ft192.9b (up 24% from 2Q 2021). Net income: Ft76.5b (up 173% from 2Q 2021). Profit margin: 40% (up from 18% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 8.0%, compared to a 5.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 01
Upcoming dividend of Ft225 per share Eligible shareholders must have bought the stock before 08 June 2022. Payment date: 16 June 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.2%). Higher than average of industry peers (2.6%). Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 15% share price gain to €19.25, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 31% over the past three years. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 12 non-independent directors. Director Laszlo Szabo was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: Ft751 (up from Ft563 in FY 2020). Revenue: Ft630.6b (up 11% from FY 2020). Net income: Ft139.6b (up 33% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Products in clinical trials Phase III: 1 Revenue exceeded analyst estimates by 1.6%. Over the next year, revenue is forecast to grow 3.3%, compared to a 8.5% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €17.88, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 14% over the past three years. Reported Earnings • Nov 10
Third quarter 2021 earnings released: EPS Ft205 (vs Ft121 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: Ft157.5b (up 14% from 3Q 2020). Net income: Ft38.2b (up 69% from 3Q 2020). Profit margin: 24% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 05
Second quarter 2021 earnings released: EPS Ft151 (vs Ft170 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: Ft155.9b (up 14% from 2Q 2020). Net income: Ft28.0b (down 11% from 2Q 2020). Profit margin: 18% (down from 23% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 28
Upcoming dividend of Ft225 per share Eligible shareholders must have bought the stock before 04 June 2021. Payment date: 14 June 2021. Trailing yield: 2.8%. Lower than top quartile of German dividend payers (3.2%). In line with average of industry peers (3.0%). Reported Earnings • May 14
First quarter 2021 earnings released: EPS Ft145 (vs Ft156 in 1Q 2020) The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: Ft140.9b (flat on 1Q 2020). Net income: Ft26.9b (down 7.3% from 1Q 2020). Profit margin: 19% (down from 21% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Feb 04
New 90-day high: €24.26 The company is up 31% from its price of €18.50 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €32.05 per share. Aankondiging • Jan 31
Felicia Group agreed to acquire wholesale and retail operations from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER). Felicia Group agreed to acquire wholesale and retail operations from Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) on January 29, 2021. The transaction is subject to antitrust approval. Is New 90 Day High Low • Jan 14
New 90-day high: €21.42 The company is up 21% from its price of €17.70 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €20.54 per share. Aankondiging • Jan 09
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) signed an asset purchase agreement to acquire Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV for approximately $260 million on December 3, 2020. Janssen will provide post-closing transitional support to facilitate the transfer of the Outside US marketing authorizations. The asset purchase agreement is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing authorizations to Richter. The acquisition of assets will be financed by existing cash balance.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV on January 7, 2021. The conditions of the closing were met, consequently the transaction was closed. Aankondiging • Dec 04
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) signed an asset purchase agreement to acquire Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV for approximately $260 million. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) signed an asset purchase agreement to acquire Outside US Evra® transdermal contraceptive patch assets of Janssen Pharmaceutica NV for approximately $260 million on December 3, 2020. Janssen will provide post-closing transitional support to facilitate the transfer of the Outside US marketing authorizations. The asset purchase agreement is complemented by a transitional business license agreement and series of other related agreements to run the business without interruption during the period required to transfer marketing authorizations to Richter. The acquisition of assets will be financed by existing cash balance. Is New 90 Day High Low • Dec 01
New 90-day high: €20.34 The company is up 3.0% from its price of €19.67 on 02 September 2020. The German market is also up 3.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.77 per share. Is New 90 Day High Low • Oct 29
New 90-day low: €17.66 The company is down 3.0% from its price of €18.22 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.54 per share. Aankondiging • Oct 02
Univfy Inc. and Gedeon Richter Announce Partnership to Launch Personalized in Vitro Fertilization Counselling Platform to Support Fertility Patients and Providers in Europe Univfy Inc. announced partnership with Gedeon Richter, to make Univfy's AI counselling platform available to patients and fertility specialists in Europe. Univfy combines AI, clinical expertise and empathy to make IVF success more predictable for women and couples navigating their family building options, while improving growth and efficiency for fertility centers. The partnership with Gedeon Richter, a global leader in women's health and reproductive medicine, will enable more individuals and couples to access their personalised Univfy PreIVF Report and Fertility Report to support physician-patient shared decision-making. 
